Straumann saw a 6.7% decline in sales for the third quarter and said that ongoing economic uncertainty will continue to impact the dental implant business worldwide.
The company reported sales of 151 million Swiss francs ($170 million U.S.) for the quarter (end-September 30), down 7% from 162 million francs ($184 million) for the same quarter a year ago.
Revenue growth in North America rose to more than 11% in local currencies during the third quarter, due to "robust sales" of implants and Straumann Allograft and the company's new intraoral scanner business.
Going forward, "the burdens of sovereign debt, the fragility of consumer confidence, and the strength of the Swiss franc" are all matters for concern, noted Straumann President and CEO Beat Spalinger in a press release.
